ERBB2 and salivary gland cancer: The urothelial cancer cohort from the phase II MyPathway basket trial showed that trastuzumab and pertuzumab achieved an ORR of 18.2% in HER2-positive metastatic urothelial cancer patients, which was lower than the ORR reported in HER2-positive salivary gland cancer (61.6%), CRC (26.2%) biliary tract cancer (BTC) (22.5%) and non-small-cell lung cancer (NSCLC) (25.9%), but higher than in pancreatic cancer (10%), ovarian cancer (8.3%) and uterine cancer (4.3%) [118].